Intrasilicone bevacizumab injection for iris neovascularization after vitrectomy for proliferative diabetic retinopathy

Ophthalmic Research

Volumn 49, Issue 1, 2012, Pages 20-24

  Salman, Abdelrahman G ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Bevacizumab; Diabetic retinopathy; Iris neovascularization; Silicone oil; Vitrectomy

Indexed keywords

BEVACIZUMAB; SILICONE OIL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; DRUG EFFICACY; DRUG SAFETY; EYE DISEASE; FEMALE; HUMAN; INTRAOCULAR PRESSURE; IRIS NEOVASCULARIZATION; MALE; NEOVASCULARIZATION (PATHOLOGY); OUTCOME ASSESSMENT; PRIORITY JOURNAL; REMISSION; VISUAL ACUITY; VITRECTOMY;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DIABETIC RETINOPATHY; FEMALE; HUMANS; INJECTIONS, INTRAOCULAR; INTRAOCULAR PRESSURE; IRIS; IRIS DISEASES; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PROSPECTIVE STUDIES; SILICONE OILS; VISUAL ACUITY; VITRECTOMY;

EID: 84866177335     PISSN: 00303747     EISSN: 14230259     Source Type: Journal    
DOI: 10.1159/000341734     Document Type: Article

References (17)

1. Avery RL: Regression of retinal and iris neo-vascularization after intravitreal bevaci-zumab (Avastin) treatment. Retina 2006; 26: 352-354.
2. Sivak-Callcott JA, O'Day DM, Gass DM, Tsai JC: Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma. Ophthalmology 2001; 108:1767-1776.
3. Ferrara N: Vascular endothelial growth factor: basic science and clinical progress. En-docr Rev 2004; 25: 581-611.
4. Ryan M, Philip J, Carmen A, et al: Shor t-term safety and efficacy of intravitreal bevaci-zumab (Avastin) for neovascular age related macular degeneration. Retina 2006; 26: 495-511.
5. Rodrigo J, Rogrio A, Daniela C, et al: Intra-vitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). Retina 2006; 26: 1006-1013.
6. Rosenfeld PJ: Intravitreal Avastin: the low cost alternative to Lucentis? Am J Ophthal-mol 2006; 142: 141-143.
7. Gallemore RP, McCuen BW: Silicone oil in vitreoretinal surgery; in Ryan SJ (ed): Retina, ed 4. St. Louis, Mosby, 2006, pp 2211-2234.
8. Teich SA, Walsh JB: A grading system for iris neovascularization: prognostic implications for treatment. Ophthalmology 1981; 88: 1102-1106.
9. Ehrenberg M, McCuen BW, Schindler RH, et al: Rubeosis iridis: preoperative iris fluores-cein angiography and periocular steroids. Ophthalmology 1984; 91:321-325.
10. Oshima Y, Sakaguchi H, Gomi F, Tano Y: Re-gression of iris neovascularization after in-travitreal injection of bevacizumab in patients with proliferative diabetic retinopa-thy. Am J Ophthalmol 2006; 142:155-158.
11. Wakabayashi T, Oshima Y, Sakaguchi H, Ikuno Y, Miki A, Gomi F, et al: Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology 2008; 115:1571-1580.
12. Cheng JY, Wong DW, Ang CL: Intraocular Avastin (bevacizumab) for neovascularisa-tion of the iris and neovascular glaucoma. A nn Acad Med Singapore 2008; 37: 72-74.
13. Grisanti S, Biester S, Peters S, Tatar O, Ziems-sen F, Bartz-Schmidt KU, Tuebingen Bevaci-zumab Study Group: Intracameral bevaci-zumab for iris rubeosis. Am J Ophthalmol 2006; 142:158-160.
14. Iliev ME, Domig D, Wolf-Schnurrbursch U, Wolf S, Sarra GM: Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol 2006; 142: 1054-1056.
15. Haritoglou C, Kook D, Neubauer A, Wolf A, Priglinger S, Strauss R, et al: Intravitreal be-vacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006; 62: 999-1005.
16. Silva Paula J, Jorge R, Alves Costa R, Ro-drigues Mde L, Scott IU: Short-term results of intravitreal bevacizumab (avastin) on anterior segment neovasculariztion in neovas-cular glaucoma. Acta Ophthalmol Scand 2006; 84:556-557.
17. Manzano RP, Peyman GA, Khan P, Kivilcim M: Testing intravitreal toxicity of bevaci-zumab (Avastin). Retina 2006; 26: 257-261.